{"name":"Talaris Therapeutics","slug":"talaris","ticker":"TALS","exchange":"NASDAQ","domain":"talaristx.com","description":"Talaris Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of transplant-related complications. The company's lead product candidate, TMC141, is a cell therapy designed to prevent graft-versus-host disease (GVHD) in patients undergoing hematopoietic stem cell transplantation. TMC141 has completed a Phase 1/2 clinical trial and is currently in Phase 3 development. Talaris Therapeutics is headquartered in Ann Arbor, Michigan, and its shares are listed on the NASDAQ stock exchange under the ticker symbol TALS.","hq":"Louisville, KY","founded":0,"employees":"","ceo":"Scott Bhagat","sector":"Transplant / Cell Therapy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":66985000,"netIncome":-73210000,"cash":309001000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Talaris Therapeutics Announces FDA Clearance of IND for TMC141","summary":"Talaris Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TMC141, enabling the company to initiate a Phase 3 clinical trial.","drugName":"TMC141","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Talaris Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Talaris Therapeutics reported its financial results for the third quarter of 2023, including a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Talaris Therapeutics Announces Collaboration with University of Michigan","summary":"Talaris Therapeutics announced a collaboration with the University of Michigan to advance the development of its cell therapy platform.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBScXRtQ0tnTHAtQ1RNeTQwUm9HcmNXWXVJUzg0NGo4b2dUVnVYSS01ekpBUlpXa1J0bDlpWlhham5ubzhYZXh4dW5yanlVR19ZSnc?oc=5","date":"2025-06-06","type":"trial","source":"Endpoints News","summary":"IPO Tracker (2021) - Endpoints News","headline":"IPO Tracker (2021)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPb2VVb2RzRkFyRTJZeTh4QUVOZ2xpcWduVmkxR0dOZGp5b0xXUFpKRVB3bVFtUU1HbUVzVmFBQ1c1NW9xblluTHZweFFTOWg0emRwYUFVNWhqNkROWGgxSWRpU3VpTlVQcGdYLTVva3FqNXNGcGFuMVpvQVBfMmZhc3ZJTUFaV1BvTDBuSDhhM1p5V3pRWldHV0hnRGU3WlhtcEhiSDkxU0FJMXBhMzlieHpn?oc=5","date":"2024-04-29","type":"pipeline","source":"citybiz","summary":"Cullinan Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer - citybiz","headline":"Cullinan Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWU5WNWVCRG1DRjFYWGZRZWFYaXppZFVBZnJtTEVnb1M2RG9WM29OV0laR2Rac2FjRmItYVBwWG5MczFKam84RGNZZXJlbVlEZnNJVThjd1M5NFB3amdBQkMyZGtzbUdJUlYxVmc3UnJobTV1R1d2dnFKNm9mSk1lRTROb1dNY1dPdnRmWW8wLWtYTE9u?oc=5","date":"2024-01-02","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2023 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOc085V0NSUjg0VHVIRmoxdWtxcnc4Mkc1RkhtLTJaWUpRclM5ODNUVlJpaDBuOXQ3dGQ1cGFYTFN0enYxZ0dLTDRrYkdFd3llMGpYU29ZVC1GSlE2bG00VVBsWkNVekJCYk5NVW5HVkZpb0FCWjRuTnY3MVdLNE1lNUxLZ2RtNWJBeHZoc2NkbGtpek5mUXd1ZDJNTW5NbWdIQTUwbDZsd3lBQTJmdDRQZXl5UHBnQk1pLTFEZ2pjRmJFa2VvbTlRWmJVd2o4ekJtSWs4?oc=5","date":"2023-06-22","type":"deal","source":"GlobeNewswire","summary":"Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement - GlobeNewswire","headline":"Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOWGRTTHZuZVdMWl95SkMxU0xwWjh0Z3N1eFpJbHFoZTl6QWNuR3g5SWFlVVBlTHJwT1ViQUY5TGI1cHpSSFAtS1N6TmxFallyT2l4eDhtcUVhMDFZVTB5Q2R6N09Xd0xYMTJJckY3cUJjM2VlaUhrYzBOMUoxZlAxWWIzamlXZ1duWXg0SzNvQVhKTVdrc2pDWkFUcw?oc=5","date":"2021-11-04","type":"pipeline","source":"pharmaphorum","summary":"Talaris therapy ends need for immune drugs in transplant patients - pharmaphorum","headline":"Talaris therapy ends need for immune drugs in transplant patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1fcFVOSGEwQVNjd3V6T05iN2VqaV9RWnpXYnFaRXRTTW1GRkFVM1ZhNTNXNll2NFJIU19lZm1aQjNLS0R5U2Z1dnR4V1RPYlVuRnoyMG1rNERod0tZRUJPdW1IU2lIdzVEV0tkaTQySEFLUW11WFdpRHM3YVI1QQ?oc=5","date":"2021-05-07","type":"pipeline","source":"Barron's","summary":"4 Companies Open for Trading. Here’s How They Did. - Barron's","headline":"4 Companies Open for Trading. Here’s How They Did. - Barron's","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Celavie Biosciences","Vita Therapeutics","Precision BioSciences"],"therapeuticFocus":["Transplant-related complications","Graft-versus-host disease (GVHD)"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":66985000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-73210000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":309001000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}